OncoMatch/Clinical Trials/NCT07209241
Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM
Is NCT07209241 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies CART-EGFR-IL13Ra2 T cells for recurrent glioblastoma.
Treatment: CART-EGFR-IL13Ra2 T cells — This is an open-label, phase 1b study to evaluate different approaches for CART-EGFR-IL13Ra2 dosing and further characterize the safety, feasibility, preliminary efficacy, and pharmacokinetics of CART-EGFR-IL13Ra2 cells in patients with EGFR-amplified glioblastoma that has recurred following prior radiotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Biomarker criteria
Required: EGFR amplification
Required: IDH1 wild-type
Prior therapy
Must have received: radiation therapy — first-line
glioblastoma, IDH-wildtype ... that has recurred following prior radiotherapy
Cannot have received: VEGF inhibitor (bevacizumab)
Receipt of bevacizumab within 3 months prior to physician-investigator confirmation of eligibility
Lab requirements
Kidney function
Serum creatinine ≤ 1.5 x ULN or estimated creatinine clearance ≥ 30 ml/min and not on dialysis
Liver function
ALT/AST ≤ 3 x ULN; Total bilirubin ≤ 2.0 mg/dL, except for patients in whom hyperbilirubinemia is attributed to Gilbert's syndrome (≤ 3.0 mg/dL)
Cardiac function
Left Ventricular Ejection Fraction (LVEF) ≥ 45% confirmed by ECHO/MUGA
Adequate organ function defined as: Serum creatinine ≤ 1.5 x ULN or estimated creatinine clearance ≥ 30 ml/min and not on dialysis. ALT/AST ≤ 3 x ULN. Total bilirubin ≤ 2.0 mg/dL, except for patients in whom hyperbilirubinemia is attributed to Gilbert's syndrome (≤ 3.0 mg/dL). Left Ventricular Ejection Fraction (LVEF) ≥ 45% confirmed by ECHO/MUGA. Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygen > 92% on room air.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Pennsylvania · Philadelphia, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify